Pr ecis: This study provides a new perspective on the inherent risks of interventional chemotherapy in cancer patients by showing how the adaption of unstable cell populations exposed to antiproliferative drugs can be acted upon by selective forces that drive the outgrowth of rapidly proliferative drug-resistant cell populations.
963
Tumor-Derived Osteopontin Reprograms Normal Mammary Fibroblasts to Promote Inflammation and Tumor Growth in Breast Cancer Yoray Sharon, Yael Raz, Noam Cohen, Amir Ben-Shmuel, Hila Schwartz, Tamar Geiger, and Neta Erez Pr ecis: These findings deepen the causative influence of a proinflammatory protein secreted by breast carcinoma cells in programming a supportive role for fibroblasts in the tumor microenvironment, with implications for understanding the etiology of advanced cancer and its therapeutic management by renormalization of the tissue microenvironment.
974
RAGE Mediates S100A7-Induced Breast Cancer Growth and Metastasis by Modulating the Tumor Microenvironment Mohd W. Nasser, Nissar Ahmad Wani, Dinesh K. Ahirwar, Catherine A. Powell, Janani Ravi, Mohamad Elbaz, Helong Zhao, Laura Padilla, Xiaoli Zhang, Konstantin Shilo, Michael Ostrowski, Charles Shapiro, William E. Carson III, and Ramesh K. Ganju Pr ecis: A signaling axis that conditions the inflammatory microenvironment in breast cancer helps drive the aggressive growth of these tumors, including deadly triple-negative tumors that occur more commonly in premenopausal women.
986

TLR2 Limits Development of Hepatocellular Carcinoma by Reducing IL18-Mediated Immunosuppression
Shinan Li, Rui Sun, Yongyan Chen, Haiming Wei, and Zhigang Tian Pr ecis: These findings illuminate a mechanism of immunosuppression in liver carcinogenesis that may assist the design of effective immunotherapies to treat hepatocellular carcinoma. Pr ecis: This study addresses the major gap in information concerning molecular subtypes of aggressive prostate cancer, where insights might help direct the development of more effective prognostic and therapeutic tools.
1035
ERBB3-Independent Activation of the PI3K Pathway in EGFR-Mutant Lung Adenocarcinomas
Xiaoling Song, Pang-Dian Fan, Amlak Bantikassegn, Udayan Guha, David W. Threadgill, Harold Varmus, and Katerina Politi Pr ecis: Activation of the PI3K pathway in EGFR mutant lung cancer cells is maintained even in the absence of the EGFR heterodimerization partner ERBB3, challenging the current thinking that ERBB3 is the main activator of PI3K in this disease setting.
1046
Interferon Regulatory Factor- Pr ecis: Understanding the activation status of various oncogenic drivers as they exist in specific treatment contexts in vivo may be important to achieve beneficial outcomes, increasing the complexity in how to use targeted drugs that were designed only with cancer cells in mind.
1102
Genetic and Pharmacologic Inhibition of eIF4E Reduces Breast Cancer Cell Migration, Invasion, and Metastasis Pr ecis: A tumor suppressor gene that functions in glioma stem-like cells acts to inhibit their expression of tissue plasminogen activator, with the provocative implication that targeting this central coagulation factor may ablate cancer stem-like functions in the brain.
1134
Host Age Is a Systemic Regulator of Gene Expression Impacting Cancer Progression
Afshin Beheshti, S ebastien Benzekry, J. Tyson McDonald, Lili Ma, Michael Peluso, Philip Hahnfeldt, and Lynn Hlatky
Pr ecis: This study offers direct support for age dependence in determining the host tumor control dynamic and provides initial mechanism-based insights into how aging modulates tumor progression in ways that may be actionable for therapy or prevention. Pr ecis: These findings illuminate the ways in which loss of the NF-kb pathway regulator NEMO (also known as IKKg) promotes liver inflammation and carcinogenesis by elevating p21, which acts in this setting to protect against the generation of DNA damage that contributes to chronic hepatitis and hepatocarcinoma formation in patients. 
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ABOUT THE COVER
miR340 is a tumor suppressor whose overexpression in human glioma-intiating cells (GIC) inhibits their proliferation, invasive, and migratory properties. Transplantation of miR340-overexpressed GICs in NOD/SCID mouse brains completely suppressed the tumor formation of malignant gliomas. Among factors related to antitumorigenesis, the transplanted GICs with miR340 overexpression showed a positive immunostain for an active form of caspase-3 in the early stage of transplantation, suggesting that antitumorigenic activity of miR340 in GICs may be due to tumor cell apoptosis. For details, see the article by Yamashita and colleagues on page 1123. To request permission to re-use all or part of this article, contact the AACR Publications Department at
